Summit Therapeutics Inc. (NASDAQ:SMMT) announced that The Lancet Oncology published primary analysis results from its global Phase 3 HARMONi trial.
Significant Progression-Free Survival Improvements
The study evaluated ivonescimab combined with platinum-doublet chemotherapy against a placebo and chemotherapy regimen.
This treatment targets patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) who experienced disease progression after using a third-generation EGFR tyrosine kinase inhibitor.
The trial data showed that patients receiving the ivonescimab combination experienced a median progression-free survival (PFS) of 6.8 months, compared to 4.4 months for the placebo group.
This represents a statistically significant improvement with a hazard ratio of 0.52. Independent radiographic reviewers confirmed these findings, noting consistent benefits across preplanned subgroups.
Manageable Safety Profile And Survival Trends
While the primary overall survival (OS) analysis showed a positive trend for the ivonescimab combination, it did not reach statistical significance at that time.
Researchers observed a manageable safety profile, reporting severe treatment-related hemorrhage events in less than 1% of patients.
Following the primary data, the company shared an updated OS analysis based on a June 2026 data cut-off.
This follow-up demonstrated a continued positive OS trend, revealing a 0.76 hazard ratio for Western patients. The efficacy and safety profile remained consistent across both Asian and Western demographics.
Upcoming Presentations And Regulatory Milestones
Summit Therapeutics will present further details from this updated data analysis at the 2026 World Conference on Lung Cancer on September 15.
Meanwhile, the Food and Drug Administration assigned a November 14, 2026, action date for the company’s Biologics License Application.
In August, Summit Therapeutics partner Akeso Inc. noted that China approved ivonescimab in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer.
SMMT Price Action: Summit Therapeutics shares were up 4.05% at $13.24 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo by Piotr Swat via Shutterstock
Login to comment